|
FDA Advisory Panel Unanimously Backs Novartis Cushing’s Disease Drug
A 10-member FDA advisory panel voted unanimously Nov. 7 to recommend approval of Novartis’ Signifor for the treatment of Cushing’s disease.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives